Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug:146:310-317.
doi: 10.1016/j.lungcan.2020.06.030. Epub 2020 Jun 26.

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Wanyuan Cui  1 , Fanny Franchini  2 , Marliese Alexander  3 , Ann Officer  4 , Hui-Li Wong  5 , Maarten IJzerman  6 , Jayesh Desai  7 , Benjamin J Solomon  7
Affiliations

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Wanyuan Cui et al. Lung Cancer. 2020 Aug.

Abstract

Background: KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggable. KRASG12C mutation confers sensitivity to KRASG12C covalent inhibitors, however its prognostic impact remains unclear. This study assesses the frequency, clinical features, prevalence of brain metastases and outcomes in KRASG12C NSCLC in a real-world setting.

Methods: Patients enrolled in the prospective Thoracic Malignancies Cohort (TMC) between July 2012 to October 2019 with recurrent/metastatic non-squamous NSCLC, available KRAS results, and without EGFR/ALK/ROS1 gene aberrations, were selected. Data was extracted from TMC and patient records. Clinicopathologic features, treatment and overall survival (OS) was compared for KRAS wildtype (KRASWT) and KRAS mutated (KRASmut); and KRASG12C and other (KRASother) mutations.

Results: Of 1386 NSCLC patients, 1040 were excluded: non-metastatic/recurrent (526); unknown KRAS status (356); ALK/EGFR/ROS1 positive (154); duplicate (4). Of 346 patients analysed, 144 (42 %) were KRASmut, of whom 65 (45 %) were KRASG12C. All patients with KRASG12C were active or ex-smokers, compared to 92 % of KRASother and 83 % of KRASWT. The prevalence of brain metastases during follow-up was similar between KRASmut and KRASWT (33 % vs 40 %, p = 0.17), and KRASG12C and KRASother (40 % vs 41 %, p = 0.74). The proportion of patients receiving one or multiple lines of systemic therapy was comparable. OS was similar between KRASmut and KRASWT (p = 0.54), and KRASG12C and KRASother (p = 0.39).

Conclusion: Patients with KRASmut and KRASWT, and KRASG12C and KRASother NSCLC have comparable clinical features, treatment and survival. While not prognostic, KRASG12C may be an important predictive biomarker as promising KRASG12C covalent inhibitors continue to be developed.

Keywords: KRAS G12C mutation; KRAS mutation; Lung cancer; Non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest No conflict of interest for WC, FF, MA, AO, H-LW, MI. JD has served as a consultant for Beigene, Lilly, Eisai, Amgen and Biocon; and institution has received research funding from Roche, Lilly, AstraZeneca/MedImmune, Beigene, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Bionomics. BJS has served as a compensated consultant or received honorarium from Amgen, Loxo Oncology, Roche/Genentech, Pfizer, Novartis, AstraZeneca, Merck and Bristol Myers Squibb.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Substances